—A Webinar from Decision Resources
Based on our U.S. Physician & Payer Forum report entitled Will the Launch of Emerging Oral Immunomodulators be a Game-Changer for the Rheumatoid Arthritis Market?, Decision Resources is offering this exclusive webinar. Because this presentation will feature major report findings, it is ONLY available to purchasers of this report.
Please contact us to learn how you can purchase this report and attend the webinar.
While U.S. rheumatologists’ confidence in the risk-benefit profiles of biologic agents has led to multi-billion dollar sales for these drugs in the treatment of rheumatoid arthritis, two agents in development have the potential to dramatically alter the treatment and reimbursement landscape for this disease. Pfizer’s tofacitinib (CP-690550) and AstraZeneca/Rigel’s fostamatinib disodium (R-788) are in Phase III trials for rheumatoid arthritis and could compete directly with the tumor necrosis factor-alpha (TNF-alpha) inhibitors because of their oral formulation, efficacy profiles and due to an anticipated lower price compared with biologic therapies. In this evolving market, the manufacturers of Orencia (Bristol-Myers Squibb) and Actemra/RoActemra (Roche/Chugai) have taken steps to protect, and potentially expand, their agents’ share by developing subcutaneous (SC) formulations of these biologics.
Decision Resources surveyed 101 U.S. rheumatologists and 20 U.S. managed care organizations’ (MCO) pharmacy directors (PDs) to assess expectations regarding the emerging novel oral DMARDs tofacitinib and fostamatinib disodium, SC formulations of Actemra and Orencia and biosimilar versions of etanercept.
This webinar, presented by Decision Resources Analyst Benjamin Guikema, Ph.D., will answer the following questions:
- What efficacy and reimbursement factors would be most instrumental in allowing tofacitinib to challenge the positioning of the TNF-alpha inhibitors? By year end 2014, which patient segments will make up the majority of tofacitinib-treated patients and which patient segments will make up the majority of fostamatinib disodium-treated patients?
- To what extent will physicians be willing to prescribe novel oral DMARDs and non-TNF-alpha inhibitor biologics as first- and second-choice treatments in conventional DMARD-refractory patients by year-end 2014? Which of the three non-TNF-alpha inhibitor biologics—Roche/Biogen Idec/Chugai/Zenyaku Kogyo’s Rituxan/MabThera, Orencia, and Actemra—will be positioned earliest in the treatment algorithm by year end 2014?
- How does surveyed MCOs’ coverage and restrictions to accessing the most recent biologic entrants—UCB/Otsuka’s Cimzia, Janssen Biotech/Merck/Janssen Biologics/Mitsubishi Tanabe’s Simponi and Actemra—compare with their biologic predecessors? What changes in reimbursement policy are surveyed MCO PDs willing to make in response to a demonstration of non-inferiority in ongoing head-to-head trials pitting Orencia SC and Actemra IV against Humira?
- What are surveyed MCOs’ expectations regarding tier positioning for tofacitinib and fostamatinib disodium in various pricing scenarios in the first year of each agent’s marketing? What step therapy restrictions are most likely to be imposed on tofacitinib? What percentages of surveyed MCO PDs are willing to require tofacitinib as a step therapy requirement before TNF-alpha inhibitors in the case that the drug shows similar efficacy against signs and symptoms and improvement in physical function as Humira? Do as many surveyed MCO PDs anticipate that, based on its current safety profile and assuming that it shows similar efficacy to the TNF-alpha inhibitors, fostamatinib disodium could be required before TNF-alpha inhibitor therapy?
Dr. Guikema will conduct a live Q & A session after the presentation.
Rheumatoid Arthritis: How Will Tofacitinib and Fostamatinib Disodium Impact the Treatment and Reimbursement Landscape?
November 2 at 10 a.m. U.S. Eastern Time, 3 p.m. Central European Time (Paris).
Webinar Details Date & Time Presentation: 30 minutes Q & A: 15 minutes |
About the Speaker
|
Benjamin Guikema, Ph.D., |
To learn how you can purchase this report and attend the webinar, please contact us using the information below. In North America In Europe In Japan |
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
